Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 22, 2024

FOLFIRI Plus Cetuximab Until Disease Progression vs FOLFIRI Plus Cetuximab With Cetuximab Maintenance for RAS/BRAF Wild-Type Metastatic Colorectal Cancer

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study
J. Clin. Oncol 2024 Jan 05;[EPub Ahead of Print], C Pinto, A Orlandi, N Normanno, E Maiello, MA Calegari, L Antonuzzo, R Bordonaro, MG Zampino, S Pini, F Bergamo, G Tonini, A Avallone, TP Latiano, G Rosati, AA Cogoni, A Ballestrero, A Zaniboni, M Roselli, S Tamberi, C Barone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading